Cargando…

Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists

[Image: see text] RNA ligands of retinoic acid-inducible gene I (RIG-I) hold significant promise as antiviral agents, vaccine adjuvants, and cancer immunotherapeutics, but their efficacy is hindered by inefficient intracellular delivery to the cytosol where RIG-I is localized. Here, we address this...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobson, Max E., Becker, Kyle W., Palmer, Christian R., Pastora, Lucinda E., Fletcher, R. Brock, Collins, Kathryn A., Fedorova, Olga, Duvall, Craig L., Pyle, Anna M., Wilson, John. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706089/
https://www.ncbi.nlm.nih.gov/pubmed/33274278
http://dx.doi.org/10.1021/acscentsci.0c00568
_version_ 1783617081807208448
author Jacobson, Max E.
Becker, Kyle W.
Palmer, Christian R.
Pastora, Lucinda E.
Fletcher, R. Brock
Collins, Kathryn A.
Fedorova, Olga
Duvall, Craig L.
Pyle, Anna M.
Wilson, John. T.
author_facet Jacobson, Max E.
Becker, Kyle W.
Palmer, Christian R.
Pastora, Lucinda E.
Fletcher, R. Brock
Collins, Kathryn A.
Fedorova, Olga
Duvall, Craig L.
Pyle, Anna M.
Wilson, John. T.
author_sort Jacobson, Max E.
collection PubMed
description [Image: see text] RNA ligands of retinoic acid-inducible gene I (RIG-I) hold significant promise as antiviral agents, vaccine adjuvants, and cancer immunotherapeutics, but their efficacy is hindered by inefficient intracellular delivery to the cytosol where RIG-I is localized. Here, we address this challenge through the synthesis and evaluation of a library of polymeric carriers rationally designed to promote the endosomal escape of 5′-triphosphate RNA (3pRNA) RIG-I agonists. We synthesized a series of PEG-block-(DMAEMA-co-A(n)MA) polymers, where A(n)MA is an alkyl methacrylate monomer ranging from n = 2–12 carbons, of variable composition, and examined effects of polymer structure on the intracellular delivery of 3pRNA. Through in vitro screening of 30 polymers, we identified four lead carriers (4–50, 6–40, 8–40, and 10–40, where the first number refers to the alkyl chain length and the second number refers to the percentage of hydrophobic monomer) that packaged 3pRNA into ∼100-nm-diameter particles and significantly enhanced its immunostimulatory activity in multiple cell types. In doing so, these studies also revealed an interplay between alkyl chain length and monomer composition in balancing RNA loading, pH-responsive properties, and endosomal escape, studies that establish new structure–activity relationships for polymeric delivery of 3pRNA and other nucleic acid therapeutics. Importantly, lead carriers enabled intravenous administration of 3pRNA in mice, resulting in increased RIG-I activation as measured by increased levels of IFN-α in serum and elevated expression of Ifnb1 and Cxcl10 in major clearance organs, effects that were dependent on polymer composition. Collectively, these studies have yielded novel polymeric carriers designed and optimized specifically to enhance the delivery and activity of 3pRNA with potential to advance the clinical development of RIG-I agonists.
format Online
Article
Text
id pubmed-7706089
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-77060892020-12-02 Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists Jacobson, Max E. Becker, Kyle W. Palmer, Christian R. Pastora, Lucinda E. Fletcher, R. Brock Collins, Kathryn A. Fedorova, Olga Duvall, Craig L. Pyle, Anna M. Wilson, John. T. ACS Cent Sci [Image: see text] RNA ligands of retinoic acid-inducible gene I (RIG-I) hold significant promise as antiviral agents, vaccine adjuvants, and cancer immunotherapeutics, but their efficacy is hindered by inefficient intracellular delivery to the cytosol where RIG-I is localized. Here, we address this challenge through the synthesis and evaluation of a library of polymeric carriers rationally designed to promote the endosomal escape of 5′-triphosphate RNA (3pRNA) RIG-I agonists. We synthesized a series of PEG-block-(DMAEMA-co-A(n)MA) polymers, where A(n)MA is an alkyl methacrylate monomer ranging from n = 2–12 carbons, of variable composition, and examined effects of polymer structure on the intracellular delivery of 3pRNA. Through in vitro screening of 30 polymers, we identified four lead carriers (4–50, 6–40, 8–40, and 10–40, where the first number refers to the alkyl chain length and the second number refers to the percentage of hydrophobic monomer) that packaged 3pRNA into ∼100-nm-diameter particles and significantly enhanced its immunostimulatory activity in multiple cell types. In doing so, these studies also revealed an interplay between alkyl chain length and monomer composition in balancing RNA loading, pH-responsive properties, and endosomal escape, studies that establish new structure–activity relationships for polymeric delivery of 3pRNA and other nucleic acid therapeutics. Importantly, lead carriers enabled intravenous administration of 3pRNA in mice, resulting in increased RIG-I activation as measured by increased levels of IFN-α in serum and elevated expression of Ifnb1 and Cxcl10 in major clearance organs, effects that were dependent on polymer composition. Collectively, these studies have yielded novel polymeric carriers designed and optimized specifically to enhance the delivery and activity of 3pRNA with potential to advance the clinical development of RIG-I agonists. American Chemical Society 2020-10-26 2020-11-25 /pmc/articles/PMC7706089/ /pubmed/33274278 http://dx.doi.org/10.1021/acscentsci.0c00568 Text en © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Jacobson, Max E.
Becker, Kyle W.
Palmer, Christian R.
Pastora, Lucinda E.
Fletcher, R. Brock
Collins, Kathryn A.
Fedorova, Olga
Duvall, Craig L.
Pyle, Anna M.
Wilson, John. T.
Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists
title Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists
title_full Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists
title_fullStr Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists
title_full_unstemmed Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists
title_short Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists
title_sort structural optimization of polymeric carriers to enhance the immunostimulatory activity of molecularly defined rig-i agonists
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706089/
https://www.ncbi.nlm.nih.gov/pubmed/33274278
http://dx.doi.org/10.1021/acscentsci.0c00568
work_keys_str_mv AT jacobsonmaxe structuraloptimizationofpolymericcarrierstoenhancetheimmunostimulatoryactivityofmolecularlydefinedrigiagonists
AT beckerkylew structuraloptimizationofpolymericcarrierstoenhancetheimmunostimulatoryactivityofmolecularlydefinedrigiagonists
AT palmerchristianr structuraloptimizationofpolymericcarrierstoenhancetheimmunostimulatoryactivityofmolecularlydefinedrigiagonists
AT pastoralucindae structuraloptimizationofpolymericcarrierstoenhancetheimmunostimulatoryactivityofmolecularlydefinedrigiagonists
AT fletcherrbrock structuraloptimizationofpolymericcarrierstoenhancetheimmunostimulatoryactivityofmolecularlydefinedrigiagonists
AT collinskathryna structuraloptimizationofpolymericcarrierstoenhancetheimmunostimulatoryactivityofmolecularlydefinedrigiagonists
AT fedorovaolga structuraloptimizationofpolymericcarrierstoenhancetheimmunostimulatoryactivityofmolecularlydefinedrigiagonists
AT duvallcraigl structuraloptimizationofpolymericcarrierstoenhancetheimmunostimulatoryactivityofmolecularlydefinedrigiagonists
AT pyleannam structuraloptimizationofpolymericcarrierstoenhancetheimmunostimulatoryactivityofmolecularlydefinedrigiagonists
AT wilsonjohnt structuraloptimizationofpolymericcarrierstoenhancetheimmunostimulatoryactivityofmolecularlydefinedrigiagonists